# Cellectis Reports Financial Results for the First Quarter 2025
Canonical URL: https://biopharmsignal.com/news/CLLS/cellectis-reports-financial-results-for-the-first-quarter-2025
Ticker: CLLS
Company: Cellectis
Source: Cellectis
Published: 2025-05-12 20:30 EST
Original Source URL: https://www.cellectis.com
## Summary

<ul style="list-style-type:circle"> <li><span style="color:#173860"><em><span style="font-size:11.0pt"><span>Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025</span></span></em></span></li> <li><span style="color:#173860"><em><span style="font-size:11.0pt"><sp

## Article Body
Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025

Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025

AstraZeneca partnership: R&D activities ongoing on three programs - one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorder

Cellectis will present novel non-viral gene editing and base editing research at the 2025 ASGCT annual meeting

Cash position of $246 million as of March 31, 2025[1] provides runway into H2 2027

New York, NY - May 12, 2025 - Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided financial results for the first quarter 2025, ending March 31, 2025, and provided a business update.

" We are making progress in our wholly-owned clinical studies and in the three programs under our strategic partnership with AstraZeneca. We will continue to focus our efforts and resources on advancing these core programs and are looking forward to the results expected over the next few months " said Andr&eacute; Choulika, Ph.D., Chief Executive Officer at Cellectis.

Pipeline Highlights

UCART Clinical Programs

BALLI-01 study evaluating lasme-cel (UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

On April 15, 2025, the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO) selected lasmecabtagene timgedleucel (lasme-cel) as recommended international non-proprietary name of UCART22 drug substance.

Cellectis continues to focus on the enrollment of patients in the BALLI-01 study and expects to present the Phase 1 dataset and late-stage development strategy for lasme-cel in r/r B-ALL in the third quarter of 2025.

NATHALI-01 study evaluating eti-cel (UCART20x22) in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL)

On April 15, 2025, the INN Expert Committee of the WHO selected etivelcabtagene erigedleucel (eti-cel) as recommended international non-proprietary name of UCART20x22 drug substance.

Cellectis continues to focus on the enrollment of patients in the NATHALI-01 study and expects to present a Phase 1 readout for eti-cel in r/r NHL in late 2025.

Research Data & Preclinical Programs

Novel Non-Viral Gene Editing and Base Editing Research

On April 28, 2025, Cellectis announced the presentation of research data on TALEN&reg;-mediated non-viral transgene insertion for advancing cellular and gene therapies, and advancements in genetic editing using TALE base editors (TALEB), at the American Society of Gene and Cell Therapy (ASGCT) annual meeting that will be held on May 13-17, 2025 in New Orleans. The data will be presented in two posters:

TALEN&reg;- Mediated non-viral Transgene Insertion for the Advancement of Cellular and Gene Therapies

In this work, Cellectis combines TALEN&reg;-mediated gene editing with non-viral transgene insertion for advancing cellular and gene therapies and explores gene insertion-efficacy and cellular health using single-stranded DNA (ssDNA) for payload delivery in different cell types.

This innovative approach has the potential to address the challenges associated with traditional lentiviral viral methods or AAV-mediated transgene insertion such as manufacturing constraints, potential genomic toxicities or limited payload size.

High fidelity C-to-T editing with TALE base editors

TALE base editors (TALEB) are fusions of a transcription activator-like effector domain (TALE), split-DddA deaminase halves, and an uracil glycosylase inhibitor (UGI). The C-to-T class of TALEB edits double-stranded DNA by converting a cytosine (C) to a thymine (T) and does not involve a DNA strand nick. Cellectis has developed a method to evaluate TALEB activity, analyzing factors affecting its efficiency. Using precise ssODN knock-in in primary T cells, the method assesses how target sequence composition and spacer variations impact TALEB performance.

Overall, the results of this study enhance the control and use of TALEB, allowing for the design of highly efficient and specific TALEB compatible with future potential therapeutic applications.

The abstracts are live on the ASGCT website. The posters will be available on Cellectis' website the first day of the event.

Partnerships

AstraZeneca Joint Research and Collaboration Agreement

Research and development activities are ongoing under three cell and gene therapy programs under the joint research and collaboration agreement entered into by Cellectis and AstraZeneca in November 2023: one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorder.

[1] Cash position includes cash, cash equivalents, restricted cash and fixed-term deposits classified as current financial assets. Restricted cash was $4.4 million as of March 31, 2025. Fixed-term deposits classified as current financial assets were $114.0 million as of March 31, 2025.
## Recent Company News
- 2026-06-25 20:30 EST — [Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026](https://biopharmsignal.com/news/CLLS/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026-28c487bb) — Source: Cellectis
- 2026-06-11 06:40 EST — [Cellectis Presents Final Phase 1 Results of Lasme-cel and  Preliminary Results on Eti-cel at EHA 2026 Congress](https://biopharmsignal.com/news/CLLS/cellectis-presents-final-phase-1-results-of-lasme-cel-and-preliminary-results-on-ea9f9ebc) — Source: Cellectis
- 2026-06-09 20:30 EST — [Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL](https://biopharmsignal.com/news/CLLS/cellectis-receives-fda-rmat-designation-for-lasme-cel-the-first-allogeneic-car-t-629c5c17) — Source: Cellectis
- 2026-05-20 20:30 EST — [Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026](https://biopharmsignal.com/news/CLLS/cellectis-annual-shareholders-general-meeting-to-be-held-on-june-25-2026) — Source: Cellectis
- 2026-05-12 13:30 EST — [Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress](https://biopharmsignal.com/news/CLLS/cellectis-to-present-clinical-data-on-lasme-cel-and-eti-cel-at-eha-2026-annual-congress) — Source: Cellectis
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)